Luye Life Sciences attends Hong Kong International Healthcare Week 

The second International Healthcare Week (IHW), organized by the Hong Kong Trade Development Council (HKTDC) opened on 16 May in Hong Kong. A series summits and communication activities were held during IHW. Two subsidiaries of Luye Life Sciences Group, Boan Biotech and Luye Medical Group, were invited to participate and discuss healthcare issues with industry leaders. 

• Boan Biotech debuted at the third "Asia Summit on Global Health", discussing new opportunities for innovation and cooperation with industry leaders

On 17 May, the 3rd Asia Summit on Global Health organized by the Government of the Hong Kong Special Administrative Region and Hong Kong Trade Development Council was opened. Jiang Hua, the chairlady and CEO of Boan Biotech was invited to participant and give a speech.

Mr. John Lee（The Chief Executive of the Government of the Hong Kong Special Administrative Region）；Ms. Yu Yanhong (Member, Leading Party Members’ Group, National Health Commission of the People’s Republic of China; Secretary, Leading Party Members' Group and Deputy Director, National Administration of Traditional Chinese Medicine) take photos with the guests attending the summit.

In the plenary session: Latest Healthcare Developments & Shifting Investment Landscape in China, the Chairlady Jiang Hua shared her insights on the future trends and investment highlights of China's healthcare and biomedical industry. 

Other guests are including Ambassador George Hara, Chairman of the Board, Alliance Forum Foundation; Group Chairman and CEO, DEFTA Partners; Prof Lo Yuk Lam, BBS, Chairman, GT Healthcare Capital Partners; President, HK Bio-Med Innotech Association; Dr Guo Tong, Vice President, Head of Sales, Greater China, IQVIA; and Ms Wang Jin, Senior Partner and China Healthcare Practice Leader, McKinsey & Company Inc.

 

Chairlady Jiang Hua introduced the experience of Boan Biotech Listed on the Main Board of SEHK at the end of last year and shared the company's latest R&D progress and future plans. She said that Hong Kong is a gathering place of global financial capital and business talents, and has a unique geographical advantage in the global supply chain. In the field of biotechnology, Hong Kong has made gratifying achievements in infrastructure construction, transformation of academic achievements, talent attraction and science park construction in recent years, which makes us look forward to the future of Hong Kong's biomedical and healthcare industry. She also said that Hong Kong has the potential to be a bridgehead for Chinese enterprises to enter the international market. Boan Biotech would also consider setting up a branch in Hong Kong to better connect with the global market, talents, capital and technology.

 

• Luye Medical Shared Its Experience in High-Quality Growth of Medical Services

The 2023 APAC Healthcare Conference was held in Hong Kong from 17th to 18th May. Representatives from leading companies in the fields of global pharmaceutical biotechnology, healthcare services, and medical devices attended the conference and discussed issues ranging from medical policies to innovative technologies. Charles Wang, Chief Executive Officer of Luye Medical Group, was invited to attend the keynote panel and shared his thoughts on the theme of "Healthcare Services – Balance of growth and profitability".

 

He said: “Good doctors and good teams are always the focus of medical services, which can improve both operational efficiencies internally and improve patients' experience externally, thereby achieving better treatment effects. At present, Luye Medical Group is committed to attracting, retaining, and cultivating talents with similar values, thus stimulating cooperation and productivity for healthy, sustainable development.”  He also introduced the latest developments of Luye Medical's business in China, Singapore, and Australia.

The panel was moderated by Kevin Qian, Managing Director and China Head of Global Asset Managers Investment Banking at Citi, with Zhiliang Tu, Founder, Chairman and CEO of Gushengtang, and Eva Huang, Managing Director of CBC Group discussing the topic from investment and Chinese medicine perspectives.

Luye Hong Kong and Singapore Offices Help China Companies and Organizations to “Go Global”

While more Chinese mainland enterprises and organizations accelerate their pace of "Go Global" in the post-epidemic era, the Group’s Hong Kong and Singapore offices, with an open mind, cooperation and win-win attitude, has been supporting their international market development and investment attraction, thus enhancing their international competitiveness with new technologies, new formats, and new models.

Since the end of 2022, the Group has successfully received more than ten city and county government delegations from Shandong, Jiangsu, Zhejiang, Sichuan provinces, conducted in-depth communication, held a number of professional exchange activities, and made full use of the group's multiple international and domestic resources to assist in "going out" and "bringing in" strategies. A series of strategic cooperation has been establishment, such as Luye Medical Rehabilitation Headquarters and Industry-Academy-Research Innovation Incubation Centre in Lishui, Jiangsu Province, which will drive domestic and overseas high-quality rehabilitation industry upstream and downstream projects’ landing in the area, forming a rehabilitation industry cluster and creating a domestic rehabilitation industry highland.

In the field of medicine, the Group assisted the China Pharmaceutical Innovation and Research Development Association (“PhIRDA") to visit Hong Kong and Singapore for the first time in three years and carried out multiple international experience exchanges with local experts from industry, learning and research to understand the policies in the field of biomedicine, investment and financing opportunities, and talents exchanges. The Group will continue to carry out in-depth cooperation during PhIRDA’s future overseas visits.

In the future, the Group will continue to deepen mutually beneficial cooperation with partners and achieve common development.

 

Luye Pharma (Latin America) Website Goes Live!

The Luye Pharmaceutical (Latin America) website has officially launched! As an external information exchange platform, the website aims to provide stakeholders in Latin America with a comprehensive overview of Luye Pharma and valuable updates about the company and its progress.

Luye Pharma Group is committed to the research and development, production, and sales of innovative drugs, with operations in more than 80 countries and regions around the world. Latin America is a high-potential emerging market where the company is deepening its global presence. Currently, Luye Pharma is expanding its business footprint in Latin America and is committed to providing high-quality, affordable, and innovative treatment solutions to patients in the region.

The newly launched Luye Pharma (Latin America) website comprehensively introduces the company's development overview, technology platform, pipeline in development, business layout, and other information from the three aspects of "global research and development", "global manufacturing", and "global market". Relevant content covers a wider audience through three languages -- Spanish, English, and Portuguese. In addition, the website also has a recruitment column to attract like-minded talent to join the company to serve the needs of local patients.

 

Jose Salum Neri, Commercial Lead of Luye Pharma Latin America, said, "We are excited to see this website officially launched and expect it to have a positive impact on our business. We believe that this website will help us attract new business partners in Latin America, which will further consolidate the company's position and image in the region. We are committed to providing our customers in Latin America with the highest quality products and services and look forward to further development and growth in the region."

Sneak peek at Luye Pharma’s (Latin America) website：http://www.luyelatam.com/

 

Seeking Innovation and Creating a Winning Future | Luye Diagnostics Co-held Precision Medicine Summit in Wuxi

On 19th May, the Wuxi Economic Development Zone Precision Medicine Industry-University-Research Transformation Summit was successfully held in Wuxi Shangxian Lake Fund Park.

The forum was hosted by the Management Committee of Wuxi Economic Development Zone, co-organized by Luye Life Sciences Group and Golden Bay Science and Technology Entrepreneurship Industrial Park in Wuxi Economic Development Zone. Policy makers, industry gurus and academics gathered to share their insights on six major fields, including genetic testing, gene editing, antibody drugs, cell therapy, high-end medical devices, medical big data and artificial intelligence.

The inaugural Morning Star Plan for Precision Medicine was released at the summit, and a signing ceremony of the Government-Industry-University-Research Strategy, and the establishment ceremony of the Precision Medicine Industry-University-Research Transformation Alliance in the Economic and Technological Development Zone were also held to promote further collaboration in the field of precision medicine.

Liu Aona, Chairprson of Luye Diagnostics Group, said: The development of precision medicine has a long way to go. To realize the transformation of scientific research achievements in diagnostic medicine and to create good products and services, it is necessary for all parties from the government, industry, and academia to cooperate and innovate, and make efforts to overcome difficulties. The government of the Wuxi Economic and Technological Development Zone has proactively created a platform for the commercialization of scientific research achievements in precision medicine. Under such policies, Luye Diagnostics and other high-quality companies have taken root in this hot spot, forming a high-quality industrial cluster. The roots are deep, and the leaves are therefore luxuriant, and in the future we can expect bloom and fruit benefiting the people and market in China. She believes the joint efforts will also promote economic growth in Wuxi and the Economic Development Zone.

Li Yaping, Deputy Secretary-General of Wuxi Municipal Government, pointed out in the opening speech: Over the years, Wuxi has unswervingly promoted the innovation-driven core strategy and the industry-led strategy of strengthening the city. Wuxi will, as always, will provide enterprises and talents with best possible resources, and join hands with elites from industry and academia to boost the development of precision medicine, thus jointly drawing a bright picture of the life sciences industry.

The Wuxi Economic and Technological Development Zone is located in the core area of the Taihu Bay Science and Technology Innovation Belt, with obvious location advantages and concentrated biomedical industries. It has established the Golden Bay Precision Medicine Science and Technology Innovation Park to attract high-quality enterprises and talents, including the Luye Diagnostics National Headquarters and the Luye Precision Medicine Industrial Cluster. As a leading enterprise, Luye Diagnostics will drive the development of the Precision Medicine Innovation Park, and is committed to building a precision medicine industry research institute, an industrial transformation platform, a clinical application platform, and an industrial investment fund. Industrialized innovation service system.

Luye Diagnostics' Recent Overseas Visits Promote International Cooperation

Recently, Luye Diagnostics paid visits to Singapore and the United Arab Emirates with the Economic and Trade delegation of Wuxi Economic Development Zone to discuss cooperation and seek common development.

In early May, the delegation went to Singapore and visited Luye Life Sciences Group, Vela Diagnostics, Envision Energy, Surbana Jurong Group, Jurong Group, Tuas Space, NEON Group, Orchard International Group and other local leading enterprises in Singapore, analyzing and discussing for cooperation opportunities (the sixth from the left is Ella Jiang, CEO of Luye Diagnostics).
 

The following 2-day visit to the UAE was very compact and fulfilling. Representatives from Luye Diagnostics and various science and innovation industrial parks in Wuxi visited Dubai and Abu Dhabi successively, visiting local government departments and six institutions including sovereign wealth funds, international investment institutions, universities and science and innovation industries. The visit and face-to-face communication greatly boosted the high-quality development of both parties.

   

Only by embracing the world can we embrace the future; and only by working together can we make steady progress. Luye Diagnostics has always been striding forward along the road of innovation and high-quality development and looks forward to joining hands with partners at home and abroad to achieve fruitful results after a series of practical and efficient exchanges.